Literature DB >> 9298685

Phenotype expression in familial combined hyperlipidemia.

K V Porkka1, I Nuotio, P Pajukanta, C Ehnholm, L Suurinkeroinen, M Syvänne, T Lehtimäki, A T Lahdenkari, S Lahdenperä, K Ylitalo, M Antikainen, M Perola, O T Raitakari, P Kovanen, J S Viikari, L Peltonen, M R Taskinen.   

Abstract

Familial combined hyperlipidaemia (FCHL) is one of the most common hereditary disorders predisposing to early coronary death. The affected family members have elevations of serum total cholesterol, triglycerides or both. Despite intensive research efforts the genetic and metabolic defects underlying this complex disorder are still unknown. To dissect the metabolism and genetics of FCHL the phenotype of an individual must be precisely defined. We assessed the influence of different diagnostic criteria on the phenotype definition and studied factors affecting the phenotype expression in 16 large Finnish families (n = 255) with FCHL. The fractile cut-points used to define abnormal lipid values had a profound influence on the diagnosis of FCHL. If the 90th percentile cut-point was used, approximately 45% of the family members were affected, in concord with the presumed dominant mode of transmission for FCHL. If the 95th percentile was used only 22% of study subjects were affected. To characterize the metabolic differences or similarities between the different lipid phenotypes, we determined very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) particles separated by ultracentrifugation. In linkage analysis no single ultracentrifugation variable could discriminate reliably affected family members from non-affected family members. Our data emphasizes the need for re-evaluation of FCHL diagnostic criteria. Preferably, the diagnosis should be based on a single, reliable metabolic marker.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9298685     DOI: 10.1016/s0021-9150(97)00134-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  Quantitative-trait-locus analysis of body-mass index and of stature, by combined analysis of genome scans of five Finnish study groups.

Authors:  M Perola; M Ohman; T Hiekkalinna; J Leppävuori; P Pajukanta; M Wessman; M Koskenvuo; A Palotie; K Lange; J Kaprio; L Peltonen
Journal:  Am J Hum Genet       Date:  2001-06-15       Impact factor: 11.025

Review 2.  Role of lipid-lowering pharmacotherapy in children.

Authors:  S Tonstad
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

3.  Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels.

Authors:  P Pajukanta; J D Terwilliger; M Perola; T Hiekkalinna; I Nuotio; P Ellonen; M Parkkonen; J Hartiala; K Ylitalo; J Pihlajamäki; K Porkka; M Laakso; J Viikari; C Ehnholm; M R Taskinen; L Peltonen
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

4.  Familial combined hyperlipidemia in a North Indian kindred.

Authors:  C S Sriram; Sheffali Gulati; Vikas Chopra; Suman Vashist; P S N Menon
Journal:  Indian J Pediatr       Date:  2005-11       Impact factor: 1.967

5.  Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia.

Authors:  Sophie Eichenbaum-Voline; Michael Olivier; Emma L Jones; Rossitza P Naoumova; Bethan Jones; Brian Gau; Hetal N Patel; Mary Seed; D John Betteridge; David J Galton; Edward M Rubin; James Scott; Carol C Shoulders; Len A Pennacchio
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-09       Impact factor: 8.311

6.  Genetic architecture of human plasma lipidome and its link to cardiovascular disease.

Authors:  Rubina Tabassum; Joel T Rämö; Pietari Ripatti; Jukka T Koskela; Mitja Kurki; Juha Karjalainen; Priit Palta; Shabbeer Hassan; Javier Nunez-Fontarnau; Tuomo T J Kiiskinen; Sanni Söderlund; Niina Matikainen; Mathias J Gerl; Michal A Surma; Christian Klose; Nathan O Stitziel; Hannele Laivuori; Aki S Havulinna; Susan K Service; Veikko Salomaa; Matti Pirinen; Matti Jauhiainen; Mark J Daly; Nelson B Freimer; Aarno Palotie; Marja-Riitta Taskinen; Kai Simons; Samuli Ripatti
Journal:  Nat Commun       Date:  2019-09-24       Impact factor: 14.919

7.  Small and dense LDL in familial combined hyperlipidemia and N291S polymorphism of the lipoprotein lipase gene.

Authors:  Antonio López-Ruiz; María M Jarabo; María L Martínez-Triguero; Maria Morales-Suárez-Varela; Eva Solá; Celia Bañuls; Marta Casado; Antonio Hernández-Mijares
Journal:  Lipids Health Dis       Date:  2009-03-31       Impact factor: 3.876

8.  High-resolution population-specific recombination rates and their effect on phasing and genotype imputation.

Authors:  Shabbeer Hassan; Ida Surakka; Marja-Riitta Taskinen; Veikko Salomaa; Aarno Palotie; Maija Wessman; Taru Tukiainen; Matti Pirinen; Priit Palta; Samuli Ripatti
Journal:  Eur J Hum Genet       Date:  2020-11-28       Impact factor: 4.246

9.  The Contribution of GWAS Loci in Familial Dyslipidemias.

Authors:  Pietari Ripatti; Joel T Rämö; Sanni Söderlund; Ida Surakka; Niina Matikainen; Matti Pirinen; Päivi Pajukanta; Antti-Pekka Sarin; Susan K Service; Pirkka-Pekka Laurila; Christian Ehnholm; Veikko Salomaa; Richard K Wilson; Aarno Palotie; Nelson B Freimer; Marja-Riitta Taskinen; Samuli Ripatti
Journal:  PLoS Genet       Date:  2016-05-26       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.